SEOUL, January 17 (AJP) - Lotte Biologics has announced plans to launch its advanced "Soluflex Link" technology, a next-generation platform for antibody-drug conjugates (ADCs), during the JP Morgan Healthcare Conference on Thursday.
ADCs are innovative cancer treatments that combine antibodies, which target cancer cells, with powerful drugs designed to kill them.
"Soluflex Link addresses stability issues commonly seen in ADC therapies and is compatible with various antibodies," said CEO James Park in his first public remarks since taking over the role in December. Park previously held executive roles at Merck, Bristol Myers Squibb, and Samsung Biologics.
The Soluflex Link platform, co-developed with Kanaph Therapeutics, uses a specialized linking agent to connect the antibody and the drug, offering improved stability and effectiveness. Lotte Biologics plans to make the technology available to researchers developing new ADC therapies.
The company is also ramping up its role as a contract development and manufacturing organization (CDMO). Its Syracuse bio-campus in New York, acquired from Bristol Myers Squibb in late 2022, has received top-tier quality ratings from both Japan's PMDA and the U.S. FDA. Additionally, Lotte is building its first manufacturing facility in Songdo, South Korea, set to be operational in 2027.
"We’re committed to expanding global partnerships," Park said, highlighting plans to supply antibodies and ADC drug components to CDMO clients across both U.S. coasts.
"With state-of-the-art automated facilities and strategic locations in Songdo and New York, we aim to become a global leader in quality drug manufacturing," Park added.
Copyright ⓒ Aju Press All rights reserved.